Trotabresib - Celgene Corporation
Alternative Names: BET inhibitor - Celgene Corporation; BMS-986378; CC 90010; QC5487; TROTA - Celgene CorporationLatest Information Update: 28 Jan 2025
At a glance
- Originator Quanticel Pharmaceuticals
- Developer Bristol-Myers Squibb; Celgene Corporation
- Class Antineoplastics; Isoquinolines; Ketones; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Glioblastoma
- No development reported Astrocytoma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Astrocytoma(Late-stage disease, Recurrent, Second-line therapy or greater, Neoadjuvant therapy) in Spain (PO)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Astrocytoma(Late-stage disease, Recurrent, Second-line therapy or greater, Neoadjuvant therapy) in USA (PO)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater, Neoadjuvant therapy) in Spain (PO)